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ABSTRACT
Oxaliplatin is a key drug in the treatment of advanced metastatic colorectal 
cancer. Despite its beneficial effects in tumor reduction, the most prevalent side-
effect of oxaliplatin treatment is a chemotherapy-induced neuropathy that frequently 
forces to discontinue the therapy. Indeed, along with direct damage to peripheral 
nerves, the chemotherapy-related neurotoxicity involves also the central nervous 
system (CNS) as demonstrated by pain chronicity and cognitive impairment (also 
known as chemobrain), a newly described pharmacological side effect. 
The presence of the blood brain barrier (BBB) is instrumental in preventing 
the entry of the drug into the CNS; here we tested the hypothesis that oxaliplatin 
might enter the endothelial cells of the BBB vessels and trigger a signaling pathway 
that induce the disassembly of the tight junctions, the critical components of the 
BBB integrity.
By using a rat brain endothelial cell line (RBE4) we investigated the signaling 
pathway that ensued the entry of oxaliplatin within the cell. We found that the 
administration of 10 µM oxaliplatin for 8 and 16 h induced alterations of the tight 
junction (TJs) proteins zonula occludens-1 (ZO-1) and of F-actin, thus highlighting 
BBB alteration. Furthermore, we reported that intracellular oxaliplatin rapidly 
induced increased levels of reactive oxygen species and endoplasmic reticulum 
stress, assessed by the evaluation of glucose-regulated protein GRP78 expression 
levels. These events were accompanied by activation of caspase-3 that led to 
extracellular ATP release. 
These findings suggested a possible novel mechanism of action for oxaliplatin 
toxicity that could explain, at least in part, the chemotherapy-related central effects.
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INTRODUCTION
Chemotherapy-induced neuropathy (CIN) is a 
frequent side effect for many of the most common cancer 
treatments and is predominantly characterized by sensory 
symptoms like pain, paresthesia and dysesthesia; motor 
and autonomic symptoms can develop dependently by 
the drug. CIN can be disabling, causing significant loss of 
functional abilities and decreasing quality of life [1]. The 
occurrence of CIN has been studied for decades and it is 
commonly associated with well-known anticancer drugs 
administration including oxaliplatin [2, 3]. CIN is thought 
to be caused by drug-induced damage to components of 
the peripheral nervous system (PNS) and this structural 
damage results in abnormal somatosensory processing in 
the central nervous system (CNS) [4]. On the other hand, 
increasing evidence suggest a direct, neurotoxic effect of 
chemotherapeutics to the CNS. A remarkable reorganization 
of spinal and supraspinal areas after anticancer treatments 
was highlighted [5, 6]. Accordingly, our group has 
demonstrated that during oxaliplatin-dependent neuropathic 
pain a significant increase in glial cells (microglia and 
astrocytes) [7, 8] as well as molecular, electrophysiological 
and redox alterations has been evidenced in spinal 
cord and many brain areas [9–11]. Furthermore, many 
studies have found evidence supporting the influence of 
chemotherapy on cognitive functioning [12–14], describing 
a new neuropsychological syndrome associated with 
cancer therapy named chemotherapy-induced cognitive 
impairment (CICI) or chemobrain characterized by 
memory, learning and motor function impairment [15–18].
Although many authors have demonstrated that 
the presence of the blood-brain barrier (BBB) limits 
access of many anticancer drugs to the brain and that the 
cerebrospinal fluid (CSF) penetration of the oxaliplatin 
is limited [19] a direct action of oxaliplatin on BBB 
endothelial cells (EC), the core element of BBB, could 
not be ruled out.
EC have been demonstrated to play a key role in 
BBB properties as they form the anatomic basis of the 
barrier [20, 21]. These cells differ fundamentally from 
other vascular endothelia in their capacity to regulate the 
passage of molecules and cells to and from the neural 
parenchyma [22]. The capillary endothelium in the brain 
is tighter than peripheral microvessels, the cytoplasm has 
an uniform thickness with no fenestrae, and a continuous 
basement membrane [23, 24]. Most importantly, EC lining 
the vascular wall have narrow junctional complexes that 
includes mainly tight junction (TJ) and adherens junction 
(AJ) proteins [25, 26]. They eliminate gaps or spaces 
between cells and prevent any free diffusion of blood-
borne substances into the brain parenchymal space [27]. 
Neurotoxics may evoke strong or subtler mechanisms 
leading to BBB disruption or dysfunction. Increased 
cerebrovascular permeability can be implemented via the 
paracellular or the transcellular route, or both [28]. Several 
molecular mechanisms participate to the dysregulation 
of interendothelial junctions: inflammatory factors such 
as TNF-α, IL-1β, IL-6, or free radicals, or bradykinin, or 
angiogenic factors such as VEGF [29–31]. These factors, 
strongly related to chemotherapy-induced neurotoxicity, 
can mediate a downregulation of junctional proteins as well 
as subcellular redistribution, cytoskeletal rearrangements 
and a direct disruption of interendothelial junctions. Thus, 
it was our purpose to identify oxaliplatin cytotoxic profile 
and the molecular pathway related to oxaliplatin-dependent 
BBB alteration in an immortalized rat brain endothelial cell 
line (RBE4 cells) that, retaining a stable phenotype of BBB 
endothelium in vivo, are a ductile and widely accepted in 
vitro model for the study of the BBB [32].
RESULTS
MTT assay
Results from the cytotoxicity assays are represented 
in Figure 1. A concentration range of oxaliplatin from 1 to 
100 μM was tested at different time points (8, 16 and 24 
hours). Results show that oxaliplatin was able to induce 
a decrease in cell viability in a dose- and time-dependent 
manner. The drug starts to alter the metabolic activity of 
RBE4 cells after 8 h (Figure 1, triangles) of treatment. 
The lowest tested concentration (1 μM) did not alter 
cell viability at any time point, whereas an oxaliplatin 
concentration of 3 μM induced a significant (*p < 0.05 vs 
control) decrease in cell viability only at 24 h (Figure 1, 
circles). On the contrary, at all time points significant (*p 
< 0.05 vs control) effects on RBE4 cells were observed at 
the highest concentration (100 µM). In the concentration 
range between 3 µM and 100 µM, cells exhibited a 
significant (*p < 0.05 vs control) and strong decrease in 
cell viability at 16 (Figure 1, squares) and 24 hours (Figure 
1, circles) after oxaliplatin treatment.
 Based on previously reported data concerning 
patients’ plasma concentration after oxaliplatin repeated 
treatments [35–37], we adopted the best experimental 
conditions that could better reflect an in vivo situation, 
mimicking chronic neuropathy. For this reason, we chose 
the concentration of 10 μM that induced a low level of 
mortality but, at the same time, enabled us to study the 
oxaliplatin effects at the cellular level.
Moreover, to ensure that the concentration of 
oxaliplatin 10 µM did not trigger the apoptotic pathway, 
we tested the expression levels of the pro-apoptotic protein 
BAX (Figure 2). The results showed that there was a 
significant (*p < 0.05 vs control) increase in the protein 
levels only at the concentration of 30 µM and after 24 h of 
exposure to the chemotherapeutic agent. 
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Immunocytochemistry for ZO-1 and F-actin 
proteins
The results related to BAX protein expression 
levels, prompted us to determine the effects of 10 µM of 
oxaliplatin on the expression and localization of ZO-1 and 
F-actin proteins on RBE4 cells at 8 and 16 hours post-
treatment using immunohistochemistry. We found that 
the TJ protein ZO-1 localized to the cell-cell junctions, 
showing a more prominent and clear immunostaining at 
the cell contacts (Figure 3A, control), as well as F-actin 
exhibited a typical, marginal pattern of localization (Figure 
3B, control). Eight hours of oxaliplatin treatment caused 
monolayer disruption, loss of ZO-1 staining, leading to 
a “zipper-like” staining pattern (Figure 3A, oxaliplatin) 
and holes that became visible between RBE4 cells, as 
well as the formation of numerous F-actin stress fibers 
instead of marginal localization (Figure 3B, oxaliplatin). 
These alterations were even more evident after 16 hours 
of treatment.
Figure 1: RBE4 cell viability. RBE4 cells (2.5 × 104 cells/well) were incubated with oxaliplatin (1–100 μM) for 8, 16 or 24 h. Viability 
was quantified by MTT assay; absorbance was measured at 570 nm. Values are expressed in percentage of control absorbance as the mean 
± S.E.M. of five independent experiments. Control condition absorbance was fixed at 100%. *p < 0.05 vs control.
Figure 2: BAX protein expression levels. Representative Western blot of the effects of oxaliplatin (10 and 30 µM) on the protein 
levels of BAX after 8, 16 and 24 h of treatment. Bars represent the mean ± S.E.M., n = 4; *p < 0.05 vs control (untreated cells). 
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Oxaliplatin-induced overproduction of 
intracellular ROS
In order to evaluate the role of oxidative stress in TJ 
alterations, we measured the intracellular ROS in RBE4 
cells at different time points after 10 µM of oxaliplatin 
using the redox-sensitive fluoroprobe dye CM-H2DCFDA 
by FACS (fluorescence-activated cell sorting) analysis, 
as previously reported [38]. As shown in Figure 4, an 
increase in ROS production was seen following incubation 
of cells with 10  µM oxaliplatin for 1 and 2 hours, which 
remain significantly increased at 4 hours compared 
to control cells (*p < 0.05 vs control). The ROS levels 
decreased quickly, and then returned to normalcy after 6 h 
of treatment (#p < 0.05 vs 1 h), indicating that the increase 
of ROS generation was rapid and transient.
Oxaliplatin-induced endoplasmic reticulum (ER) 
stress in RBE4 cells
We then assessed whether the ROS increase 
induced ER stress. To this end, we evaluated GRP78 
protein expression levels in RBE4 cells treated with 10 
µM oxaliplatin for 8 and 16 h by immunoblot analysis 
on total cellular homogenates. Values were normalized to 
β-actin protein expression. As shown in Figure 5, 10 μM 
oxaliplatin significantly (*p < 0.05 vs control) up-regulated 
GRP78 about three times compared to the control cells 
(Figure 5, light grey bar) at 8 h after the chemotherapy 
administration. This effect was time-dependent because 
the protein expression decreased (Figure 5, dark grey bar) 
to values comparable to that of control cells at 16 h of 
oxaliplatin treatment (^p < 0.05 vs 8 h).
Taken together, these data indicated that after 
oxaliplatin treatment RBE4 cells underwent ER stress.
Oxaliplatin treatment elicits caspase-3 activation
Considering that ER stress can induce the activation 
of caspase-3 [39], we checked the activation of this 
downstream signal of ER stress evaluating the caspase-3 
enzymatic activity (Figure 6A) in the oxaliplatin-treated 
RBE4 cells using the EnzChek® Caspase-3 Assay Kit. We 
found that oxaliplatin significantly (*p < 0.05 vs control) 
activated the caspase 3 at 8 h of treatment (Figure 6A, 
light grey bar). Also, oxaliplatin-activated caspase-3 
reaction was confirmed by Western blot assay (Figure 6B, 
light grey bar) showing an upregulation of the cleaved 
form of the protease. Moreover, in Figure 6A the result 
showed a time-dependent increase of caspase-3 activity 
that at 16 h of oxaliplatin treatment returned to control 
levels (^p < 0.05 vs 8 h) (Figure 6A, dark grey bar). 
Oxaliplatin-dependent extracellular ATP release
To characterize if RBE4 cells extrude ATP in 
response to oxaliplatin and eventually the mechanisms 
through which it occurs, firstly we evaluated the 
Figure 3: Effect of oxaliplatin on immunostaining for ZO-1 junctional protein and F-actin in RBE4 cells. In (A) asterisks 
show holes formed between endothelial cells. Arrows indicate fragmentation, indicative for loss of junctional immunostaining. Figure (B) 
shows the oxaliplatin-dependent appearance of numerous stress fibers. Original magnification 400×. Bar: 50 μm. Each experimental point was 
performed in triplicate, for three different set of experiments. Pictures are representative of fifteen field captured for each experimental point.
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extracellular ATP release in RBE4 cells that underwent 
10 μM oxaliplatin treatment. In cultures exposed for 8 
h to oxaliplatin, baseline ATP release was significantly 
(*p < 0.05 vs control) elevated as compared with control 
cells (Figure 7, light grey bar). The phenomenon 
was transient since after 16 h of treatment with the 
chemotherapy agent the ATP levels returned to values 
comparable to those of control cells (^p < 0.05 vs 8h) 
(Figure 7, dark grey bars). 
Oxaliplatin-dependent ATP release is PANX1 
independent
In order to verify if ATP release is dependent on 
pannexin-1 (PANX1) activation, we decided to examine 
whether RBE4 cells express PANX1 by immunoblot 
analysis. Figure 8A shows that RBE4 cells clearly expressed 
anti-PANX1 (~55 kDa) immunoreactivity in relatively high 
density as compared to β-actin standard protein levels. 
Figure 4: Evaluation of ROS generation. (A) Time-course of ROS production by H2DCFDA fluorescence in control and in 10 
µM oxaliplatin-treated RBE4 cells by FACS analysis. (B) The reported values (mean ± S.E.M.) are representative of five independent 
experiments, each performed in triplicate; *p < 0.05 vs control; #p < 0.05 vs 1 h.
Figure 5: GRP78 expression levels in RBE4 cells treated with oxaliplatin. Immunoblot analysis at 8 and 16 h exposure to 
10 μM oxaliplatin and quantification of GRP78 expression at 8 and 16 h. Control condition was arbitrarily set as 100% and results are 
expressed as mean ± S.E.M. Results are representative of at least three independent immunoblots. Significant at *p < 0.05 vs control and 
^p < 0.05 vs 8 h.
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 The role for PANX1 in ATP release in RBE4 
cells was then examined. RBE4 cells were treated 
with oxaliplatin for 8 and 16 h, and ATP extrusion 
was measured in the presence and absence of the 
selective PANX1 inhibitor 10Panx. We observed that the 
pretreatment with 10Panx did not result in significantly 
blunt oxaliplatin-dependent ATP release (Figure 8B). 
 Finally we assessed whether caspase-3 induced 
PANX1 opening in RBE4 cells by evaluating ATP release 
after treatment with the AC-DEVD-CHO caspase-3 
inhibitor. Results (Figure 8C) showed that the application 
of AC-DEVD-CHO did not attenuate the ATP extrusion.
Since neither the pharmacological inhibition of 
PANX1 nor the caspase-3 inhibition did not prevent the 
Figure 6: Caspase-3 activity in RBE4 cell after oxaliplatin treatment. (A) Caspase-3 activity, revealed by fluorogenic peptide-
based assay and (B). upregulation of caspase-3 cleavage, revealed by Western blot assay in RBE4 cells, post 10 μM oxaliplatin treatment 
for 8 and 16 h. β-actin was used as an internal control. Control condition was arbitrarily set as 100 % and results are expressed as mean ± 
S.E.M. All oxaliplatin treatment experiments were conducted independently in triplicate. Significant at *p < 0.05 vs control and ^p < 0.05 
vs 8 h.
Figure 7: Oxaliplatin-dependent release of ATP. Extracellular ATP release from RBE4 cells in the presence of 10 μM oxaliplatin. 
Control condition was arbitrarily set as 100% and results are expressed as mean ± S.E.M. n = 3, *p < 0.05 vs control; ^p < 0.05 vs 8 h. All 
oxaliplatin treatment experiments were conducted independently in triplicate.
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ATP spillage, we interpreted these data as showing that 
PANX1-mediated ATP release was not responsible for the 
ATP extrusion.
DISCUSSION
To study the mechanisms involved in the generation 
of oxaliplatin neurotoxicity, we have explored the 
specific cellular and molecular processes underlying the 
blood brain barrier endothelial cells events that occur in 
the presence of the anticancer drug. Using a rat brain 
endothelial cell line (RBE4 cells), we demonstrated that 
oxaliplatin administration caused significant changes in 
the junctional and cytoskeletal apparatus of endothelial 
cells, thus reducing their tightness. These oxaliplatin-
dependent alteration of the BBB could be, at least in part, 
associated with higher distribution of molecules that cross 
a defective BBB, and act in the CNS cooperating in pain 
chronicization.
Our data are in accordance with reported evidence 
that BBB, BSCB (Blood Spinal Cord Barrier), and BNB 
(Blood Nerve Barrier) disruptions participate in the 
complex mechanisms that initiate or maintain neuropathic 
pain [40–43].
Data concerning the mechanism of endothelial 
cellular uptake of oxaliplatin that is strictly dependent 
on the OCT2 (Organic Cation Transporter) [34], as well 
as the presence of these channels on the RBE4 plasma 
membrane [33] let us to hypothesized a direct interaction 
between oxaliplatin and BBB endothelial cells. Once 
inside the cells, oxaliplatin triggers an intracellular 
signaling pathway that results in a transient and reversible 
alteration (a sort of loosening) of the barrier itself.
Special characteristics of RBE4 cells include 
the presence of tight junctions. Structurally, the inter-
endothelial tight junction complexes comprising the 
membrane proteins occludin and claudins and membrane-
directed scaffolding proteins, such as ZO-1, contribute 
to the physical barrier nature of BBB and strictly limit 
the molecular/cellular influx from circulation [44]. 
Moreover, ZO-1 serves to anchor tight junctions (TJs) to 
the actin cytoskeleton in the cell [45–47] and F-actin has 
a critical role in establishing inter-endothelial junctional 
integrity and defining the peripheral morphological belt 
of endothelial cells [48, 49]. The re-distribution of major 
TJ proteins can result in reduced endothelial barrier 
tightness [50]. We evaluated the TJ protein ZO-1 and 
the cytoskeletal F-actin in order to evidence oxaliplatin-
induced physiopathologic alteration. As a result, we found 
that oxaliplatin induced the dislocation of ZO-1 and the 
formation of F-actin stress fibers. 
Previous studies have shown the important 
role of oxidative stress in the toxicity of oxaliplatin 
[11, 37, 51–53]. An excessive production of ROS can alter 
endothelial cells integrity by cytoskeletal rearrangements 
and redistribution of TJ proteins, triggering a loss of 
cellular interaction and increasing their permeability 
[54–57]. We therefore hypothesized that oxaliplatin, 
once entered the endothelial cells by OCT2 might have 
an effect on ROS production, which could possibly be 
accompanied by TJ dislocation. In the present study, it has 
shown that oxaliplatin induced a time-dependent increase 
in ROS production, indicating that oxaliplatin-dependent 
oxidative stress could be an important signal involved in 
the disruption of the integrity of the endothelial junctional 
apparatus. 
In response to oxidative stress mediated by ROS, 
accumulation of unfolded or misfolded proteins triggers 
the cellular adaptive procedure known as ER stress 
[58, 59]. By mediating the shutdown of general protein 
synthesis and increasing the production of molecular 
chaperones, including glucose-regulated protein 78 
(GRP78), ER stress is designed to be protective [60–63]. 
Recently, ER stress has been shown to play a detrimental 
role on TJs integrity [64]. In fact, ER stress can 
also accelerate ROS production both in the ER and 
mitochondria [65–67], that in turn activate apoptotic 
signaling pathway [68, 69]. Considering that in our 
Figure 8: PANX1 channels expression in RBE4 cells and release of ATP during oxaliplatin treatment with 10Panx 
and AC-DEVD-CHO. Western blot densitometry analysis of PANX1 protein expression levels in RBE4 cells (A). ATP quantification 
assay performed in the presence of 100 μM of 10Panx (B), or 100 μM AC-DEVD-CHO (C) demonstrating that both PANX1 and caspase-3 
inhibitors did not affect the ATP release. Assays were performed in triplicate. Data are expressed as mean ± S.E.M. Data are representative 
of three independent experiments. *p < 0.05 vs control; ^p < 0.05 vs 8 h.
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condition the mitochondria-dependent pro-apoptotic 
protein BAX was not activated, we decided to investigate 
the changes in GRP78 expression levels. Our findings 
showed that GRP78 is induced in a time-dependent 
manner, suggesting that ER stress is activated at 8 h after 
oxaliplatin treatment and that ROS could be the initiator 
of the ER stress.
It is well known [63, 64, 66–70] that the ER stress 
response is a mechanism that the cell puts in place in order 
to react to perturbations in ER homeostasis, during which 
GRP78 functions as a cytoprotective protein. Thus, the 
oxaliplatin-dependent upregulation of GRP78 could be 
to relieve the ER stress and restore cell function. It has 
been also suggested that the caspase-3 activation is one of 
the mechanisms that operate such protection, recognizing 
and removing overproduced ROS [71–74]. According to 
these data, our results showed an oxaliplatin-dependent 
activation of caspase-3 in absence of a parallel activation 
of the apoptotic signalling cascade (demonstrated by the 
lack of an increase in BAX protein expression levels). 
On the other hand, other authors have demonstrated that 
caspase-3, cleaving the PANX1 autoinhibitory C-terminal 
domain, induces the functional activation of PANX1 [75], 
a channel known to have a prominent role in the release 
of ATP [53, 76]. Indeed, recent findings revealed that 
chemotherapeutic drugs induce ATP release [77] that, 
in turn, leads to degradation of tight junctions, such as 
ZO-1 [78]. Furthermore, Boyd-Tressler and co-authors 
have fully demonstrated that diverse chemotherapy 
agents, induce functional activation of PANX1 [10, 79]. 
Driven by these results, we hypothesized that oxaliplatin-
dependent caspase-3 activation could elicit an ATP 
spillage by PANX1 channels. To our knowledge this work 
demonstrates for the first time that RBE4 cells express 
PANX1 channels, confirming previous data showing that 
these cells are a useful in vitro model to study the BBB 
[32, 80]. Moreover, we demonstrated that oxaliplatin 
induces an ATP release and that this leakage is independent 
of the PANX1 opening. This result is not surprising since 
the caspase-3-mediated mechanism of PANX1 activation 
is closely related to the onset of the apoptotic pathway 
[81], a condition that does not occur in our experimental 
condition. 
Moreover, this data agrees with the maintenance 
of ATP release in the presence of a caspase-3 inhibition. 
A possible, early, homeostatic signaling mediated 
by caspase-3 activation is suggested. By contrast, 
the cellular mediator able to evoke the release of the 
excitotoxic molecule ATP remains unclear deserving 
further research.
In summary, our data provide evidence of a 
chemotherapy-dependent BBB alterations that, starting 
from ROS formation, activates the ER stress/ATP release 
signalling pathway in RBE4 cells. We have conclusively 
shown that activation of this pathway, causes alterations 
of the TJ protein ZO-1 and of the cytoskeletal protein 
F-actin. These findings contribute to identify the signal 
pathways of chemotherapy-induced opening of the BBB 
and emphasizes the importance of dissecting in detail 
the molecular mechanism that alters the BBB during 
chemotherapy treatment in order to establish potential 
therapeutic targets in the treatment of chronic pain 
management.
MATERIALS AND METHODS
Cell culture and treatments
The rat brain endothelial cell line RBE4 was kindly 
provided by Dr Vincenzo Giuseppe Nicoletti (Department 
of Biomedical Sciences, University of Catania, Italy). 
Cells (up to passage 20) were grown and maintained in 
alpha-minimal essential medium (alpha-MEM)/Ham’s 
F10 (1:1) (GIBCO, Thermo Fisher Scientific, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 2 mM L-glutamine (EuroClone, 
Milano, Italy) and 1 ng/ml basic fibroblast growth factor 
(bFGF) (Thermo Fisher Scientific, Milano, Italy) at 37° C, 
5% CO2 in humidified atmosphere. The growth medium 
was routinely changed 2–3 times per week. For each 
experimental set-up, the cells were seeded on appropriate 
support for 24 h in complete growth medium. The day of 
the stimulation, the complete growth medium was replaced 
with starvation medium (without FBS and without bFGF) 
containing appropriate stimuli at different concentration.
10Panx (Proteogenix, Schiltigheim, France) was 
dissolved in 1% DMSO (dimethyl sulfoxide) to obtain 1 
mM solution and then diluted in physiological medium 
at final concentration of 100 μM in the presence of 
oxaliplatin for 8 or 16 h. This concentration was chosen 
accordingly with previous published data [10, 82, 83]. 
The caspase-3 inhibitor AC-DEVD-CHO (N-Ac-Asp-Glu-
Val-Asp-CHO) (Calbiochem, Milan, Italy) was incubated 
for 2 hours at a concentration of 100 µM before oxaliplatin 
treatment. A non-toxic effect of AC-DEVD-CHO at this 
concentration has been demonstrated previously [65].
MTT assay
Cell viability was evaluated by the reduction of 
3-(4,5-di-methylthiozol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) by mitochondrial dehydrogenase, that 
directly reflects the activity of mitochondria, and can be 
considered an indirect measurement of cell viability. RBE4 
cells were plated into 96 multiwell plates, at the density of 
2.5 × 104 cells/well, in their appropriate complete growth 
medium. The following day, the cells were starved as 
described above and treated with different concentrations of 
oxaliplatin (1–3–10–30–100 µM), for 8, 16 and 24 h. After 
treatment, the starvation medium containing stimuli was 
removed and substituted with 1 mg/mL MTT (in starvation 
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medium without phenol red). The chromogenic solution 
was incubated for at least 20 min. at 37° C. The formazan 
crystals formed were dissolved by adding 100 μl of DMSO 
in each well and the absorption at 570 nm was read using a 
microplate reader (MultiskanFC™ microplate photometer, 
ThermoFisher Scientific, Milan, Italy). Each experimental 
point was performed in quintuplicate, for three times.
Western blotting
RBE4 cells, at the density of 3.5 × 106 cells, were 
plated in Petri dishes in their appropriate complete growth 
medium. After 24 h the cells were serum starved and 
stimulated with oxaliplatin 10–30 µM, for 8, 16, and 24 
h. After treatments, the medium was removed and cells 
were scraped in cold PBS (Phosphate Buffer Saline). The 
cell suspensions were centrifuged at room temperature 
(RT) for 10 min. at 1000 rpm. The pellets obtained were 
treated with Mem-PER™ Plus Membrane Protein Extraction 
Kit (Thermo Fisher Scientific, Milan, Italy) following 
the manufacture instruction, to isolate the integral and 
attached membrane proteins isolated from the cytosolic 
proteins. The protein concentration was evaluated by the 
Bradford method and equal amounts of protein (15 µg) were 
separated on a 12% polyacrylamide gel by electrophoreses 
and transferred onto nitrocellulose membrane (Porablot 
NPC, MACHEREY-NAGEL, Milan, Italy). After 1 h 
blocking with 3% bovine serum albumin (BSA) in Tris-
buffered saline containing 0.1% Tween 20 (Tween-TBS) 
at RT, the blots were incubated in Tween-TBS/3% BSA 
overnight at 4° C with the following primary antibodies; 
rabbit primary antibody for 78 kDa glucose-regulated 
protein (GRP78) (ThermoFisher Scientific, Milan, Italy), 
for cleaved caspase-3 (Cell Signalling, Euroclone, Milan, 
Italy), for BCL2 associated X protein (BAX) (Santa Cruz 
Biotechnology, Milan, Italy), and goat primary antibody for 
(PANX1) (Santa Cruz Biotechnology) at 1:500, 1:1000 and 
1:300, and 1:500, respectively. After washing with Tween-
TBS, the goat anti-rabbit HRP secondary antibodies (Santa 
Cruz Biotechnology) was added at 1:5,000 dilution in 
Tween-TBS for 1 h at room temperature (RT), and washed 
again. Proteins were detected with the Amersham ECL 
Plus Western Blotting Detection Reagent (GE Healthcare, 
Milan, Italy). Protein expression levels were then quantified 
by the ImageJ analysis software (ImageJ, National Institute 
of Health, USA, http://imagej.nih.gov/ij). β-actin (1:10000 
dilution) (Santa Cruz Biotechnology) normalization was 
performed for each sample. Each experiment was performed 
three times, in triplicate.
ZO-1 tight junction and F-actin 
immunofluorescent labeling
RBE4 cells were seeded on sterilized cover 
slips (lodged in a 6 multiwell plate) in the number of 
1.5 × 105 cells, in their appropriate complete growth 
medium. After 24 h the cells were serum starved and 
stimulated with oxaliplatin 10–30 µM, for 8, and 16 h. 
After treatments, the medium was removed and each 
cover slip was washed twice with cold PBS followed 
by fixation with paraformaldehyde 3.7% (for F-actin) 
in PBS for 10 min. at room temperature or cold 
methanol (for Zonula Occludens-1, ZO-1) for 20 min. 
After fixation, two more washes with cold PBS were 
performed, the cover slips were dried at RT for at least 
1 h. The fixed cells where rinsed in cold PBS for three 
time and permeabilized with a 0.1% solution of TRITON 
X-100 in PBS for 10 min at RT. Following, cells were 
washed three times with PBS and then incubated for 
15 min. in a blocking solution (1% BSA in PBS) at RT. 
Each cover slip was incubated overnight at 4° C with 
the rabbit primary antibody anti-ZO1 (1:50) or with 
Alexa-488-conjugated phalloidin (F-actin) (1:200; 
ThermoFisher Scientific, Milan, Italy), in 1% BSA. The 
day after, cells were washed three times with PBS and 
each cover slip was incubated in goat anti-rabbit (for 
ZO-1) immunoglobulin G (IgG) secondary antibody, 
conjugated with Alexa Fluor 568 (1:200; Invitrogen, 
Milan, Italy) for 1 h at RT. Then (for ZO-1 and F-actin) 
after counterstaining with DAPI (4’,6-diamidin-2-
fenilindolo; 1:2000 dilution; Invitrogen, Milan, Italy) 
for 5 min at RT, cover slip glasses were mounted using 
Fluoromount anti-fade solution (ThermoFisher Scientific, 
Milan, Italy) on cover slides. Fluorescent signals were 
detected at 400× total magnification (five microscopic 
fields for each experimental point) by a motorized Leica 
DM6000B microscope equipped with a DFC350FX 
camera. Negative controls were performed by omitting 
the primary antibody to confirm the specificity of primary 
antibodies used and by omitting the second antibody 
to reveal autofluorescent labeling (data not shown). 
Fifteen pictures from each field were captured. The data 
shown represent the typical data from three independent 
experiments that yielded similar results. Each experiment 
was performed in triplicate.
Quantification of intracellular ROS by flow 
cytometry
RBE4 cells were plated in Petri dishes in their 
appropriate complete growth medium, reaching about 
80% of confluence. After that, the cells were starved as 
reported above and stimulated with 10 µM of oxaliplatin, 
for 1, 2, 4, 6 and 8 h. After each treatments, cells where 
washed twice with DMEM w/o phenol red and detached 
from Petri dishes surface by trypsin/EDTA and centrifuged 
at 1000 rpm for 5 min. at room temperature. The pellets 
were gently resupended in DMEM w/o phenol red and 
labelled with 1 µM CM-H2DCFDA (Life Technologies, 
ThermoFisher Scientific, Milan, Italy). The tubes were 
gently mixed and dark incubated at 37° C for 20 min. After 
labelling, cells were centrifuged again, the supernatant 
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discard and the pellets obtained were gently resuspended 
in DMEM w/o phenol red, and immediately analyzed 
using a FACSCanto flow cytometer (Becton–Dickinson, 
San Jose, CA, USA).
The sample flow rate was adjusted to about 
103 cells/s. For a single analysis, the fluorescence 
properties of about 2.5 × 104 RBE4 cells were collected. 
Each experiment was performed three times, in triplicate.
Caspase-3 enzimatic activity
RBE4 cells were plated in 6-well plates (5 × 105/well) 
in appropriate complete growth medium. The following 
day, cells were starved and stimultated with oxaliplatin 
10–30 µM for 8 and 16 h. After treatment, cells were 
scraped in 100 μl lysis buffer (200 mM Tris–HCl buffer, 
pH 7.5, containing 2 M NaCl, 20 mM EDTA, and 0.2% 
Triton X-100). Fifty µl of the supernatants were incubated 
with 25 µM fluorogenic peptide caspases 3 substrate 
rhodamine 110 bis-(N-CBZ-L-aspartyl-L-glutamyl-L-va- 
lyl-L-aspartic acid amide) (AC-DEVD-CHO; Molecular 
Probes) at 25° C for 30 min. The amount of cleaved 
substrate in each sample was measured in a 96-well plate 
fluorescent spectrometer (Perkin-Elmer; excitation at 
496 nm and emission at 520 nm). Each experiment was 
performed three times, in triplicate.
Extracellular ATP quantification
RBE4 cells were plated in 6-well plates (5 × 105/
well) in appropriate complete growth medium. The 
following day, cells were starved and stimultated with 
oxaliplatin 10–30 µM for 8 and 16 h. After treatment, the 
medium was harvested and 50 µl were processed following 
the manufacture’s procedure (ATPlite – Luminiscence ATP 
Detection Assay System, PerkinElmer Italia, Milan, Italy). 
The extracellular ATP was quantified by luminescence 
using a VICTOR microplate reader (PerkinElmer, Milan, 
Italy). Each experiment was performed three times, in 
triplicate.
Statistical analysis
Statistical analyses were performed by Two-
way ANOVA followed by the Mann–Whitney test. 
All assessments were made by researchers blinded to 
treatments. Data were analysed using “Origin 9” software 
(OriginLab, Northampton, USA). Differences were 
considered significant at p < 0.05.
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